AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
Completed
- Conditions
- Osteoarthritis (OA)Rheumatoid Arthritis (RA)Ankylosing Spondylitis (AS)
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5383
- Registration Number
- NCT01577563
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Korean Post-marketing Surveillance for Onglyza®
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3433
- Registration Number
- NCT01575483
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 921
- Registration Number
- NCT01572792
- Locations
- 🇺🇸
Forest Investigative Site 1852, Fall River, Massachusetts, United States
🇺🇸Forest Investigative Site 1924, Baltimore, Maryland, United States
🇨🇦Forest Investigative Site 2203, Toronto, Ontario, Canada
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT01569074
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects
Phase 1
Completed
- Conditions
- SafetyPharmacokinetics
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT01568281
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 266
- Registration Number
- NCT01563978
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation
Completed
- Conditions
- Gastric UlcerDuodenal Ulcer
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1634
- Registration Number
- NCT01562600
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf
Completed
- Conditions
- Non Small Cells Lung Cancer
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT01562665
- Locations
- 🇦🇪
Research Site, Alain - AbuAhabi, United Arab Emirates
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
Completed
- Conditions
- Relapsing Reflux EsophagitisRepeatedly Recurring Esophagitis
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 647
- Registration Number
- NCT01562639
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer
Completed
- Conditions
- Local Advanced or Metastatic Postmenopausal Breast Cancer
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 153
- Registration Number
- NCT01561443
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation